Cormorant Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Cormorant Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,500,000	Closed	-$35.5M	–	114
2020 Q3	$35.5M	Buy	+2,500,000	New	+$24.9M	1.37%	25
2018 Q4	–	Sell	-500,000	Closed	-$2.9M	–	76
2018 Q3	$2.9M	Sell	500,000 -73,208	-13%	-$413K	0.19%	59
2018 Q2	$3.44M	Hold	573,208	–	–	0.25%	51
2018 Q1	$4.13M	Sell	573,208 -26,792	-4%	-$203K	0.31%	43
2017 Q4	$4.38M	Hold	600,000	–	–	0.46%	39
2017 Q3	$3.09M	Hold	600,000	–	–	0.55%	42
2017 Q2	$2.64M	Buy	+600,000	New	+$3.32M	0.44%	50

Other funds holding TRIL

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Cormorant Asset Management's TRIL Position: Q4 2020 in Review

Cormorant Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2020, closing a stake of 2,500,000 shares — an estimated $35.5M sold.

Cormorant Asset Management first reported a position in TRIL in Q2 2017 and held it in 7 quarters. The position peaked at $35.5M in Q3 2020. 131 funds tracked by Wall St. Rank hold TRIL as of Q4 2020.

Cormorant Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2020 after selling out during the quarter.
Cormorant Asset Management sold 2,500,000 Trillium Therapeutics Inc. shares in Q4 2020, an estimated $35.5M.
Cormorant Asset Management first reported a position in Trillium Therapeutics Inc. in Q2 2017 and held it in 7 quarters.
Cormorant Asset Management's Trillium Therapeutics Inc. position peaked at $35.5M in Q3 2020.
131 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2020.

Based on Cormorant Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.